论文部分内容阅读
吲哚胺2,3-双加氧酶(indoleamine 2,3-dioxygenase,IDO)是人体内肝外色氨酸代谢限速酶,可通过介导色氨酸耗竭及其代谢产物调节机体抗肿瘤免疫,参与肿瘤炎性微环境的形成,促进肿瘤血管新生等。IDO抑制剂在治疗不同恶性肿瘤的临床试验中,尤其是与免疫治疗、放疗和化疗等结合的联合治疗中,均取得了相对较好的疗效。因此,目前在恶性肿瘤多维治疗模式下,IDO在恶性肿瘤发生和发展中的作用以及IDO抑制剂治疗恶性肿瘤的价值,有待进一步阐明。本文对IDO与恶性肿瘤的研究进展进行综述。
Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting enzyme in extrahepatic tryptophan metabolism in the human body, which mediates antitumor activity of the body by mediating tryptophan depletion and its metabolites Immune, participate in the formation of tumor inflammatory microenvironment, promote tumor angiogenesis and so on. IDO inhibitors in the treatment of different malignancies in clinical trials, especially with the combination of immunotherapy, radiotherapy and chemotherapy, have achieved relatively good results. Therefore, the role of IDO in the occurrence and development of malignant tumors and the value of IDO inhibitors in the treatment of malignant tumors are yet to be further elucidated in the current multidimensional treatment of malignant tumors. This article reviews the progress of IDO and malignant tumors.